- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Defining Alopecia Areata Severity and Navigating Treatment Options
Author(s):
An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.
Video content above is prompted by the following:
- Describe your approach to initiating treatment in patients with alopecia areata. At what point do you consider systemic treatment for your patients?
- What factors guide your treatment decisions (severity, patient characteristics, patient expectations, etc)?
- Briefly discuss the systemic agents that are currently FDA approved for alopecia areata, including their mechanism of action as well as efficacy and safety data.
- Ritlecitinib (JAK3/TEC inhibitor)
- Baricitinib (JAK 1/2 inhibitor)
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
